companydata.dkcompanydata.dk

Afyx Therapeutics A/S: Financial statements 2020

CVR: 38793594

Source: annual report 2020, Danish Business Authority

01/01/2020 – 31/12/2020

Afyx Therapeutics A/S (CVR 38793594) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -585,934 and a net result of DKK -1,506,650 compared with DKK -1,569,660 the year before. Equity in the 2020 report amounted to DKK 4,696,027. The solvency ratio was 77%. The company had 2 employees in the financial year.

Gross Profit
DKK -585,934
Profit/Loss
DKK -1,506,650
Equity
DKK 4,696,027
Total Assets
DKK 6,095,001
Employees
2

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2020--586K-1.5M4.7M2
2019--1.1M-1.6M1M1

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is Afyx Therapeutics A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2020

Afyx Therapeutics A/S: The 2019 annual report is outSep 7, 2020

Afyx Therapeutics A/S has published its annual report for 2019. Gross profit came to DKK -1,134,301, and the net result was DKK -1,569,660.

About Afyx Therapeutics A/S

Afyx Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2017. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Inphena A/S and Inphena ApS. The management consists of Claus Juan Møller-San Pedro. The board consists of Ole Baadsgaard (chair), Claus Juan Møller-San Pedro, Pia Leah Møller-San Pedro and Søren Mohrsen Kjær. The company is owned by Afyx Capital ApS. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK 23,138,320 and a net result of DKK 1,518,132 compared with DKK -3,810,585 the year before. Equity in the 2025 report amounted to DKK 36,178,254.

Source: annual report 2025, Danish Business Authority

Other financial years